Author: Murray, Eleanor; Perry, Martin
Title: Off-label use of rituximab in systemic lupus erythematosus: a systematic review Cord-id: vjtms6p6 Document date: 2010_2_13
ID: vjtms6p6
Snippet: Considerable interest in the efficacy of rituximab (a monoclonal CD20 antibody) in patients with systemic lupus erythematosus (SLE) has been generated due to its unique mode of action, culminating in a series of randomized and open trials, and case reports. However, this use is off-license and two significant RCTs have reported negative findings, reopening the debate on clinical benefit. This review of the available data suggests that rituximab induces B-cell depletion in 95% of patients, and a
Document: Considerable interest in the efficacy of rituximab (a monoclonal CD20 antibody) in patients with systemic lupus erythematosus (SLE) has been generated due to its unique mode of action, culminating in a series of randomized and open trials, and case reports. However, this use is off-license and two significant RCTs have reported negative findings, reopening the debate on clinical benefit. This review of the available data suggests that rituximab induces B-cell depletion in 95% of patients, and a significant reduction in disease activity is achieved with a relatively good safety profile in patients with SLE.
Search related documents:
Co phrase search for related documents- action mechanism and low affinity: 1, 2, 3
- activity index and longitudinal study: 1, 2, 3, 4, 5
- live vaccine and longitudinal study: 1
Co phrase search for related documents, hyperlinks ordered by date